Abstract: Disclosed herein are compositions comprising topiramate and bioxome, redoxome, HA, extracellular vesicles (EV), or PRP extracellular vesicles, or any combination thereof. Further provided herein are methods for treating dermatological conditions, and methods for testing said compositions.

Abstract: A bioreactor is provided, comprising a housing extending along a vertical axis and defining an internal cavity therewithin, top and bottom covers at opposite ends of the housing, and a plurality of ports, each configured to facilitate fluid communication between the internal cavity and the exterior of the bioreactor. The internal cavity has a frustoconical shape, the frustoconical shape being formed such that horizontal cross-sections are coaxial about a line which is angled with respect to the vertical axis.

Abstract: This disclosure is directed to compounds and pharmaceutical compositions for treating and preventing viral diseases, as Covid-19. Among others, the invention relates to the use of ribonucleases and bioxoms, exosomes or combination thereof in the preparations and use of pharmaceutical formulations for the treatment of said disease. In addition, the invention relates to the use of immune cells and ribonucleases in the preparation and use of pharmaceutical formulations for the treatment of said disease.

Abstract: A cell-culture bioreactor operative to provide real-time reactor management in the fields of stir control, sparge control, and heat management responsively to wireless sensor feedback to optimize operating conditions to maximize cell-culture yield; and a bioreactor comprising: a vessel, having an open top; a headplate, configured to seal the vessel's open top; and a stirring device, comprising at least two independent stirring elements; wherein each of the stirring elements is configured to independently stir media accommodated within the vessel.

Abstract: A mobile processing laboratory (MPL) is provided, configured for facilitating performing therewithin a cell therapy process. The MPL comprises a portable enclosure; one or more pieces of laboratory equipment for carrying out the cell therapy process and being housed within the enclosure; a plurality of sensors, each configured to measure information regarding the environment, cellular material of the process, and/or one of the pieces of laboratory equipment; and a computer system configured for management of the cell therapy process. The computer system is configured to facilitate collecting data from the sensors, and to optimize one or more activities associated with performance of the cell therapy process based on data collected from one or more other MPLs configured for performing therewithin substantially the same cell therapy process.

Abstract: This invention relates to methods and compositions for treatment and prevention of Avian Influenza. Specifically, the invention relates to the use of immunoglobulins obtained from a subject immune to Avian Influenza in the preparation and use of pharmaceutical preparations for the treatment of Avian Influenza.